SEER
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a discount to book value, but expensive relative to its meager revenue.
- Low Price-to-Book ratio (0.43)
- High Price-to-Sales (6.81)
- Negative Forward P/E
- No Graham Number due to lack of earnings
Growth rates are anemic compared to the sector average of 124.77%.
- Slight improvement in EPS growth YoY
- Revenue growth (5%) is insufficient for biotech sector standards
- High cash burn rate implied by operating margins
Long-term historical trend is overwhelmingly bearish.
- Recent 1-month price recovery
- 5-year return of -96%
- Consistent failure to achieve profitability over 22 quarters
Strong balance sheet liquidity is the only factor preventing immediate insolvency.
- Low debt levels
- Strong current ratio
- Piotroski F-Score of 1/9
- Negative ROE and ROA
Non-dividend paying growth/distressed stock.
- No dividend history
- No capacity to pay dividends
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SEER and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SEER
Seer, Inc.
Primary
|
-96.0% | -48.6% | +1.5% | -7.4% | +14.9% | +18.3% |
|
DH
Definitive Healthcare Corp.
Peer
|
-97.5% | -89.8% | -57.4% | -66.5% | -13.7% | -13.0% |
|
MDXH
MDxHealth SA
Peer
|
-82.2% | -35.5% | +37.2% | -49.0% | -33.1% | +4.4% |
|
FONR
FONAR Corporation
Peer
|
+3.3% | +15.4% | +48.2% | +20.1% | +0.7% | +0.1% |
|
HYPR
Hyperfine, Inc.
Peer
|
-88.1% | -17.1% | +81.4% | -30.9% | +2.5% | +7.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SEER
Seer, Inc.
|
BEARISH | $112.84M | - | -25.1% | -% | $2.0 | |
|
DH
Definitive Healthcare Corp.
|
NEUTRAL | $111.79M | - | -40.4% | -57.5% | $1.07 | Compare |
|
MDXH
MDxHealth SA
|
BEARISH | $109.92M | - | -2440.4% | -31.1% | $2.14 | Compare |
|
FONR
FONAR Corporation
|
NEUTRAL | $117.26M | 16.18 | 6.0% | 7.1% | $18.61 | Compare |
|
HYPR
Hyperfine, Inc.
|
NEUTRAL | $119.21M | - | -79.0% | -262.3% | $1.21 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | HORN DAVID R. | President | Sale | 7,743 | $15,447 |
| 2026-02-18 | FAROKHZAD OMID | Chief Executive Officer | Sale | 24,385 | $48,646 |
| 2026-02-03 | HORN DAVID R. | President | Stock Award | 79,000 | - |
| 2026-02-03 | FAROKHZAD OMID | Chief Executive Officer | Stock Award | 697,162 | - |
| 2025-12-09 | FAROKHZAD OMID | Chief Executive Officer | Stock Award | 3,555,195 | - |
| 2025-12-09 | MCGUIRE TERRANCE G | Director | Stock Award | 4,088 | - |
| 2025-11-19 | HORN DAVID R. | President | Sale | 6,797 | $13,400 |
| 2025-11-19 | FAROKHZAD OMID | Chief Executive Officer | Sale | 33,838 | $66,708 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Past News Coverage
Recent headlines mentioning SEER from our newsroom.